跳至主要内容
临床试验/NCT00006476
NCT00006476已完成1 期

A Phase I Study of Intravesicular Suramin in Recurrent Superficial Bladder Cancer

Cancer Research UK2 个研究点 分布在 1 个国家目标入组 15 人开始时间: 2000年10月最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
已完成
入组人数
15
试验地点
2

研究概览

简要总结

RATIONALE: Suramin may stop the growth of bladder cancer by stopping blood flow to the tumor.

PURPOSE: Phase I trial to study the effectiveness of suramin in treating patients who have recurrent bladder cancer.

详细描述

OBJECTIVES:

  • Determine the maximum tolerated dose (MTD) of suramin in patients with recurrent superficial bladder cancer.
  • Confirm that there is no significant systemic absorption of this drug when administered intravesically in these patients.

OUTLINE: This is a dose escalation study.

At approximately 14-18 days after surgical resection of bladder tumor(s), patients receive intravesicular suramin via urethral catheter installation into the bladder over 2 hours weekly for 6 weeks in the absence of disease progression or unacceptable toxicity.

Cohorts of 3-6 patients receive escalating doses of suramin until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients develop dose-limiting toxicity.

研究设计

研究类型
Interventional
主要目的
Treatment

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

研究者

申办方类型
Other

研究点 (2)

Loading locations...

相似试验

Suramin in Treating Patients With Recurrent Bladder... | 临床试验